Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYLYNK-009: Olaparib + Pembrolizumab vs Chemotherapy + Pembrolizumab in TNBC
NCT04191135Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of olaparib in triple-negative breast cancer (TNBC) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival and Overall Survival. Started Dec 2019; status: terminated.
02
Drugs
olaparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04191135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191135.